Vertex Pharmaceuticals Inc. / Ma
Congress has disclosed 13 buys and 18 sells of VRTX (Vertex Pharmaceuticals Inc. / Ma) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
Round-trip watch Still on the books
Members who disclosed buying VRTX and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.
| Member | Entry (last buy) | Entry price | Now | vs entry | Status |
|---|---|---|---|---|---|
| Alan Armstrong | 2026-03-27 | $433.07 | $566.11 | +30.7% | in profit |
| Julia Letlow | 2024-10-23 | $470.05 | $566.11 | +20.4% | in profit |
Price as of 2026-11-02. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).
Fundamentals · FY2026 Valuation
Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Health. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.
how it's calculated
how it's calculated
how it's calculated
Legislation Related Legislation
Recent bills in this stock's sector (Health). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.
| Bill | Title | Policy area | Latest action |
|---|---|---|---|
| HR 10887 | Protecting Consumer Access to Generic Drugs Act of 2026 | Health | 2026-10-22 |
| HR 10874 | Medicare Low Income Subsidy Equality Act of 2026 | Health | 2026-10-22 |
| HR 10858 | CARE for Blood Cancer Act of 2026 | Health | 2026-10-22 |
| HR 10810 | National Patient Safety Board Act of 2026 | Health | 2026-10-15 |
| HR 10824 | Stroke Education and EMS Care Improvement Act of 2026 | Health | 2026-10-15 |
32 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| David Taylor | House | SELL ◆ insider convergence | Self · David Taylor Trust > Schwab Joint Brokerage #1 (Home Grown) | 2026-08-26 | 8 days | +1.9% | $1K–$15K 0.3% of NW |
53.7 | ↗ filing |
| Alan Armstrong | Senate | BUY ◆ insider divergence | Self | 2026-03-27 | 116 days | +11.3% | $1K–$15K | 99.1 | ↗ eFD |
| David Taylor | House | SELL ◆ insider convergence | Self · David Taylor Trust > Sardinia Ready Mix 401(k) - Dave | 2026-01-29 | 1 days | -1.2% | $1K–$15K 0.3% of NW |
29.6 | ↗ filing |
| David Taylor | House | BUY ◆ insider convergence · strong | Self · David Taylor Trust > Schwab Joint Brokerage #1 (Home Grown) | 2025-08-07 | 12 days | +4.0% | $1K–$15K 0.3% of NW |
64.7 | ↗ filing |
| Lisa McClain | House | SELL ◆ insider divergence · strong | Spouse · Charles Schwab Brokerage Account 924 | 2025-06-11 | 63 days | -12.5% | $1K–$15K 0.1% of NW |
82.7 | ↗ filing |
| Lisa McClain | House | SELL ◆ insider divergence · strong | Spouse · Charles Schwab Brokerage Account 924 | 2025-06-10 | 64 days | -12.3% | $1K–$15K 0.1% of NW |
89.5 | ↗ filing |
| Jefferson Shreve | House | SELL ◆ insider convergence | Self · CRT - Standard Unit Trust | 2025-05-12 | 3 days | -1.1% | $15K–$50K <0.1% of NW |
53.7 | ↗ filing |
| Byron Donalds | House | SELL ◆ insider convergence | Self · Moran Wealth IRA | 2025-03-20 | 18 days | -7.0% | $1K–$15K 0.3% of NW |
64.8 | ↗ filing |
| Byron Donalds | House | SELL ◆ insider convergence | Spouse · Moran Wealth IRA | 2025-03-20 | 18 days | -7.0% | $1K–$15K 0.3% of NW |
64.8 | ↗ filing |
| Jefferson Shreve | House | BUY ◆ insider divergence | Self · CRT - Standard Unit Trust | 2025-02-24 | 5 days | -0.4% | $15K–$50K <0.1% of NW |
69.2 | ↗ filing |
| Lisa McClain | House | BUY ◆ insider divergence | Spouse · Charles Schwab Brokerage Account 548 | 2024-12-11 | 243 days | -20.0% | $1K–$15K 0.1% of NW |
97.3 | ↗ filing |
| Julia Letlow | House | BUY ◆ insider divergence | Self · Merrill Lynch Investment Account #025 | 2024-10-23 | 292 days | -20.3% | $1K–$15K 1.0% of NW |
66.0 | ↗ filing |
| Thomas Tuberville | Senate | OTHER | Joint | 2024-05-03 | 824 days | — | $1K–$15K | 98.8 | ↗ eFD |
| Greg Stanton | House | SELL ◆ insider convergence | Spouse | 2023-10-24 | 2 days | — | $1K–$15K 0.5% of NW |
40.4 | ↗ filing |
| Greg Stanton | House | BUY ◆ insider divergence | Spouse | 2023-09-26 | 25 days | — | $1K–$15K 0.5% of NW |
75.9 | ↗ filing |
| William Keating | House | BUY | Self · Bill's IRA | 2022-03-29 | 34 days | — | $1K–$15K 0.3% of NW |
75.9 | ↗ filing |
| Peter Meijer | House | SELL | Self | 2021-01-28 | 6 days | — | $1K–$15K | 75.9 | ↗ filing |
| Dean Phillips | House | BUY | Self | 2020-12-18 | 20 days | — | $1K–$15K <0.1% of NW |
75.9 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint | 2019-09-19 | 18 days | — | $1K–$15K <0.1% of NW |
8.6 | ↗ filing |
| Donna Shalala | House | SELL | Self | 2019-06-24 | 6 days | — | $1K–$15K | 40.4 | ↗ filing |
| Donna Shalala | House | BUY | Self | 2019-04-18 | 12 days | — | $1K–$15K | 75.9 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint | 2019-04-11 | 28 days | — | $1K–$15K <0.1% of NW |
10.6 | ↗ filing |
| Gilbert Cisneros | House | SELL | Self | 2019-02-26 | 9 days | — | $15K–$50K 0.3% of NW |
56.6 | ↗ filing |
| Gilbert Cisneros | House | SELL | Self | 2019-01-31 | 13 days | — | $1K–$15K 0.1% of NW |
75.9 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint | 2018-06-01 | 116 days | — | $1K–$15K <0.1% of NW |
15.7 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint | 2018-05-01 | 147 days | — | $1K–$15K <0.1% of NW |
22.3 | ↗ filing |
| Josh Gottheimer | House | BUY | Joint | 2017-07-19 | 385 days | — | $1K–$15K <0.1% of NW |
40.4 | ↗ filing |
| Josh Gottheimer | House | BUY | Joint | 2017-04-13 | 482 days | — | $1K–$15K <0.1% of NW |
75.9 | ↗ filing |
| Thomas MacArthur | House | BUY | Joint | 2016-11-02 | 29 days | — | $1K–$15K | 22.3 | ↗ filing |
| Thomas MacArthur | House | BUY | Joint | 2016-11-01 | 30 days | — | $1K–$15K | 40.4 | ↗ filing |
| Michael Conaway | House | SELL | Spouse | 2016-09-12 | 3 days | — | $1K–$15K | 75.9 | ↗ filing |
| Thomas MacArthur | House | SELL | Joint | 2016-02-02 | 28 days | — | $1K–$15K | 75.9 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in VRTX — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
Of the congressional trades in VRTX, 7 coincided with corporate insiders moving the same way within 60 days, and 7 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-07-02 | McKechnie Duncan | C-suite | SELL 10b5-1 | $800K | ↗ EDGAR |
| 2026-07-02 | Tatsis Ourania | C-suite | SELL 10b5-1 | $787K | ↗ EDGAR |
| 2026-07-01 | Liu Joy | C-suite | SELL 10b5-1 | $416K | ↗ EDGAR |
| 2026-06-26 | Bozic Carmen | Other | SELL 10b5-1 | $288K | ↗ EDGAR |
| 2026-06-18 | Bozic Carmen | Other | SELL 10b5-1 | $471K | ↗ EDGAR |
| 2026-06-15 | Bozic Carmen | Other | SELL 10b5-1 | $1.8M | ↗ EDGAR |
| 2026-06-05 | Bozic Carmen | Other | SELL 10b5-1 | $785K | ↗ EDGAR |
| 2026-06-01 | Liu Joy | C-suite | SELL 10b5-1 | $364K | ↗ EDGAR |
| 2026-05-29 | Bozic Carmen | Other | SELL 10b5-1 | $888K | ↗ EDGAR |
| 2026-05-15 | Bozic Carmen | Other | SELL 10b5-1 | $614K | ↗ EDGAR |
| 2026-05-15 | Bunnage Mark E. | C-suite | SELL 10b5-1 | $15K | ↗ EDGAR |
| 2026-05-12 | Bozic Carmen | Other | SELL 10b5-1 | $3.1M | ↗ EDGAR |
| 2026-05-04 | Bhatia Sangeeta N. | Director | SELL 10b5-1 | $135K | ↗ EDGAR |
| 2026-05-01 | Liu Joy | C-suite | SELL 10b5-1 | $469K | ↗ EDGAR |
| 2026-04-01 | Liu Joy | C-suite | SELL 10b5-1 | $439K | ↗ EDGAR |
| 2026-03-27 | Bozic Carmen | Other | SELL 10b5-1 | $1.1M | ↗ EDGAR |
| 2026-03-13 | Bozic Carmen | Other | SELL 10b5-1 | $1.1M | ↗ EDGAR |
| 2026-03-11 | McKechnie Duncan | C-suite | SELL 10b5-1 | $1.3M | ↗ EDGAR |
| 2026-03-04 | McKechnie Duncan | C-suite | SELL 10b5-1 | $1.2M | ↗ EDGAR |
| 2026-03-02 | Liu Joy | C-suite | SELL 10b5-1 | $442K | ↗ EDGAR |
| 2026-02-27 | Bozic Carmen | Other | SELL 10b5-1 | $1.1M | ↗ EDGAR |
| 2026-02-27 | Kewalramani Reshma | C-suite | SELL 10b5-1 | $192K | ↗ EDGAR |
| 2026-02-27 | Kewalramani Reshma | C-suite | SELL 10b5-1 | $58K | ↗ EDGAR |
| 2026-02-27 | Kewalramani Reshma | C-suite | SELL 10b5-1 | $116K | ↗ EDGAR |
| 2026-02-27 | Kewalramani Reshma | C-suite | SELL 10b5-1 | $1.2M | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| Congress | 2026-08-26 | David Taylor | SELL | $1K–$15K |
| ◆ insider | 2026-07-02 | McKechnie Duncan C-suite 10b5-1 | SELL | $800K |
| ◆ insider | 2026-07-02 | Tatsis Ourania C-suite 10b5-1 | SELL | $787K |
| ◆ insider | 2026-07-01 | Liu Joy C-suite 10b5-1 | SELL | $416K |
| ◆ insider | 2026-06-26 | Bozic Carmen Other 10b5-1 | SELL | $288K |
| ◆ insider | 2026-06-18 | Bozic Carmen Other 10b5-1 | SELL | $471K |
| ◆ insider | 2026-06-15 | Bozic Carmen Other 10b5-1 | SELL | $1.8M |
| ◆ insider | 2026-06-05 | Bozic Carmen Other 10b5-1 | SELL | $785K |
| ◆ insider | 2026-06-01 | Liu Joy C-suite 10b5-1 | SELL | $364K |
| ◆ insider | 2026-05-29 | Bozic Carmen Other 10b5-1 | SELL | $888K |
| ◆ insider | 2026-05-15 | Bozic Carmen Other 10b5-1 | SELL | $614K |
| ◆ insider | 2026-05-15 | Bunnage Mark E. C-suite 10b5-1 | SELL | $15K |
| ◆ insider | 2026-05-12 | Bozic Carmen Other 10b5-1 | SELL | $3.1M |
| ◆ insider | 2026-05-04 | Bhatia Sangeeta N. Director 10b5-1 | SELL | $135K |
| ◆ insider | 2026-05-01 | Liu Joy C-suite 10b5-1 | SELL | $469K |
| ◆ insider | 2026-04-01 | Liu Joy C-suite 10b5-1 | SELL | $439K |
| Congress | 2026-03-27 | Alan Armstrong | BUY | $1K–$15K |
| ◆ insider | 2026-03-27 | Bozic Carmen Other 10b5-1 | SELL | $1.1M |
| ◆ insider | 2026-03-13 | Bozic Carmen Other 10b5-1 | SELL | $1.1M |
| ◆ insider | 2026-03-11 | McKechnie Duncan C-suite 10b5-1 | SELL | $1.3M |
| ◆ insider | 2026-03-04 | McKechnie Duncan C-suite 10b5-1 | SELL | $1.2M |
| ◆ insider | 2026-03-02 | Liu Joy C-suite 10b5-1 | SELL | $442K |
| ◆ insider | 2026-02-27 | Bozic Carmen Other 10b5-1 | SELL | $1.1M |
| ◆ insider | 2026-02-27 | Kewalramani Reshma C-suite 10b5-1 | SELL | $192K |
FAQ Common questions
How much has Congress traded VRTX?
13 disclosed buys and 18 sells of VRTX (Vertex Pharmaceuticals Inc. / Ma) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade VRTX?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.